Our community effort to identify SARS-CoV-2 inhibitors was organized as a challenge, where academic and industry researchers worldwide were asked to form teams to virtually screen at least a billion small molecules each and then submit 10,000 virtual molecules as potential inhibitors for SARS-CoV-2 progression, within the timeframe May-June 2020. In response to the announcement to join, 130 teams registered, of which 31 made the submission deadline. In addition to compound lists, teams had to deliver a report outlining the methods used (see Supporting Information Section 1). Of those, 20 teams were admitted after peer-review of their reports by an ad-hoc scientific committee. Overall, a four-step process was used during the challenge (Figure ). The aim put forward to the teams was to find a < 100 nM binder to a SARS-CoV-2 protein or human receptor of choice, which should ideally have a 100-fold reduction of live SARS-CoV-2 viral replication in whole cell assays. The teams were initially free to identify the most promising protein targets. The following sections will describe the four processes in detail, followed by a discussion and conclusions.